Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.64 |
| ▸ | NAMPT | P43490 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405900 | 1.00 | HDAC1 (0.64) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL2406383 | 0.92 | HDAC1 (0.63) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL2406387 | 0.92 | HDAC1 (0.63) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL209779 | 0.84 | HDAC1 (0.60) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL209778 | 0.84 | HDAC1 (0.60) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL2495531 | 0.83 | HDAC1 (0.59) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL210919 | 0.80 | HDAC1 (0.53) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL210232 | 0.80 | HDAC1 (0.53) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL210231 | 0.80 | HDAC1 (0.53) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL2409622 | 0.80 | HDAC1 (0.58) | HDAC1NAMPTHDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | claimed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2134680-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008109994-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-09-18 | — | — | WO | claimed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | claimed |
| CN-101679239-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2014-12-10 | — | — | CN | disclosed |
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | disclosed |
| US-8030344-B2 | Such as (S)-2-(Dimethylamino)ethyl-1-(4-(2-aminophenylcarbamoyl)-phenyl)pyrrolidin-3-ylcarbamate for treating cell proliferative disorders | METHYLGENE INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-2134680-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109994-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885NAMPT 498/4885HDAC3 4/4885 |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885NAMPT 498/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.